XBIT XBiotech Inc
Price (delayed)
$7.06
Market cap
$215.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$36.54M
XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally
Highlights
XBIT's revenue has dropped by 100% year-on-year
XBIT's gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of XBIT
Market
Valuations
Earnings
Shares outstanding
30.46M
Market cap
$215.07M
Enterprise value
$36.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$34.8M
EBITDA
-$33.07M
Free cash flow
-$24.53M
Per share
Balance sheet
Liquidity
EPS
-$1.16
Free cash flow per share
-$0.81
Book value per share
$6.46
Revenue per share
$0
TBVPS
$7.08
Total assets
$215.56M
Total liabilities
$18.85M
Debt
$10M
Equity
$196.7M
Working capital
$173.5M
Debt to equity
0.05
Current ratio
11.13
Quick ratio
11
Net debt/EBITDA
5.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.6%
Return on equity
-16.5%
Return on invested capital
-168.9%
Return on capital employed
-17.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XBIT stock price
How has the XBiotech stock price performed over time
Intraday
0%
1 week
5.85%
1 month
16.31%
1 year
55.16%
YTD
76.5%
QTD
37.35%
Financial performance
How have XBiotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.93M
Net income
-$35.01M
Gross margin
N/A
Net margin
N/A
XBIT's revenue has dropped by 100% year-on-year
XBIT's gross profit has dropped by 100% year-on-year
XBiotech's net income has decreased by 23% YoY and by 14% from the previous quarter
The company's operating income fell by 23% YoY and by 4.1% QoQ
Growth
What is XBiotech's growth rate over time
Valuation
What is XBiotech stock price valuation
P/E
N/A
P/B
1.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
XBiotech's EPS has decreased by 23% YoY and by 14% QoQ
The P/B is 36% higher than the last 4 quarters average of 0.8 but 16% lower than the 5-year quarterly average of 1.3
The equity has declined by 14% year-on-year and by 6% since the previous quarter
XBIT's revenue has dropped by 100% year-on-year
Efficiency
How efficient is XBiotech business performance
XBIT's ROIC has shrunk by 108% QoQ
The return on equity has declined by 38% year-on-year and by 18% since the previous quarter
XBIT's ROA is down by 33% YoY and by 16% QoQ
Dividends
What is XBIT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did XBiotech financials performed over time
The current ratio has plunged by 76% YoY and by 7% from the previous quarter
XBIT's quick ratio has dropped by 76% year-on-year and by 8% since the previous quarter
The debt is 95% lower than the equity
The equity has declined by 14% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.